$2.220
-0.020 (-0.89%)Al cierre
Noticias de WOK
Eventos de WOK
Work Medical Technology Group Ltd Trading Halted, News Pending
Work Medical Technology Group Ltd trading halted, news pending
Work Medical Technology Group Ltd Trading Halted
Work Medical Technology Group Ltd trading halted, volatility trading pause
WORK Medical Enters Strategic Cooperation Agreement with Novabioplus
WORK Medical announced that it has entered into a strategic cooperation agreement with Novabioplus. The two parties aim to jointly develop a "Data-Model-Application" trinity of next-generation intelligent medical models. The long-term initiative aims to integrate WORK Medical's digital transformation of AI-driven healthcare with Novabioplus' extensive protein data resources and application scenarios, unlocking the latent value of biological data assets. Pursuant to the agreement, the parties agree to integrate WORK Medical's AI algorithms expertise with Novabioplus' protein datasets and multi-dimensional biological reagent platforms to propel the R&D of AI-driven protein antibody therapeutics.
WORK Medical Technology Signs Exclusive Distribution Agreement with Shanghai Benke
WORK Medical Technology Group, through its subsidiary, Work Medical Treatment Equipment Co., announced that its subsidiary, Hunan Saitumofei Medical Treatment Technology Co., entered into a one-year exclusive distribution agreement with Shanghai Benke Medical Technology Co. to promote and distribute its newly launched AI-Automated Blood Cell Morphology Analyzer in East China throughout 2026. The collaboration is expected to accelerate market access and drive large-scale commercialization of the new product. Pursuant to the Agreement, Hunan Saitumofei has granted Shanghai Benke exclusive distribution rights for the Analyzer in East China, covering Jiangsu Province, Shanghai Municipality, and Zhejiang Province -- core markets within China's economically dynamic Yangtze River Delta region -- from January 1 to December 31, 2026. The Agreement establishes a minimum annual sales target of RMB 10M. Shanghai Benke has prepaid a performance bond of RMB 1M, which will be deducted from the final payment or refunded without interest upon achievement of the sales target.
WORK Medical Technology Subsidiary Receives Approval for AI Blood Cell Analyzer
WORK Medical Technology announced that its subsidiary, Hunan Saitumofei received manufacturing approval from the Hunan Provincial Medical Products Administration for its Class II medical device, the Artificial Intelligence-Automated Human Blood Cell Morphology Analyzer. This regulatory approval represents a milestone in WORK Medical's research and development strategy and is expected to position the Company's new AI-driven device as a key growth catalyst.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.